Relaxin treatment reduces angiotensin II-induced vasoconstriction in pregnancy and protects against endothelial dysfunction

Grants

Funding Acknowledgements

This work was supported by Australian National Health & Medical Research Council Project Grants (LJP, NH, MT), an Australian Research Council Linkage Grant (LJP, MT), and a University of Melbourne Research Scholarship and the David Lachlan Hay Postgraduate Writing Up-Award (SAM). NJH received salary support from The University of Melbourne (CR Roper Fellowship). This project was partially funded by Novartis Pharma AG, who provided the relaxin as a condition of an Australian Research Council Linkage Grant. LJP was also a paid consultant for Novartis Pharma AG. Novartis Pharma AG had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.